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• Most women with active seizures are often encouraged to continue their 
antiepileptic medications during pregnancy to avoid serious fetal or maternal 
complications.  
• Levetiracetam (LEV) is a newer antiepileptic drug used as adjunctive therapy in 
patients with refractory partial seizures with or without secondary generalization.  
• Because of its broad-spectrum activity, LEV is becoming increasingly used in women 
with epilepsy of childbearing potential, during pregnancy and thus also during 
lactation. 
• First generation anti-epileptics are known to cause Major Congenital Malformations 
(MCM) and developmental problems.  
• However, there is paucity of literature on information regarding safety of 
Levetiracetam (second generation), use in pregnancy and breastfeeding.  
• The purpose of the present study was to summarize the scientific evidence behind 
use of LEV during pregnancy and lactation.  
 
• Furthermore, studies assessing the neurocognitive development until one year 
supported the use of LEV during pregnancy compared to other drugs in the 
same group.  
• However, very few studies (n=2) assessed the effect of LEV on poor neonatal 
adaptation syndrome (PNAS) or neurocognitive behavior after one year of age or 
more 
Figure 1: PRISMA Chart  
• To review the fetal safety of Levetiracetam during pregnancy.  
• To review the safety of Levetiracetam in breastfeeding.  
• Following databases (Medline, Psych info, Science Direct, Lactmed, and Midlands’s 
medicine) and reference list of the articles were searched from inception until 
May2016.  
• The study included all interventional, observational, randomized control trials, and 
case series or case studies written in English.  
• Study selection was done by two independent researchers (BT, PAR) and then 
compared. 
• Quality assessment was performed before including the study in the final review.  
• Data extraction tool was developed and was conducted by two independent 
reviewers.  
• LEV use during pregnancy can be considered safe; although the long term safety is 
still unknown.  
• Limited evidence suggests use of LEV (upto 3500 mg daily) during breastfeeding is 
safe and is not expected to be associated with any adverse events.  
• A systematic review protocol has been published in PROSPERO International 
prospective register of systematic reviews.  
• The authors would like to acknowledge Nurhaina Sara Lakibul to design the poster.  
 
 
• A total of 17 studies (9 pregnancy registries, 2 population based cohorts,  
      questionnaire based surveys and 3 case series) were included. 
• Out of 2350 LEV monotherapy exposed women, approximately 2% (n=43) were 
       reported to have MCM.  
• The rates of MCM varied across the literature like when LEV was used in 
combination with other anti-epileptics.  
• No major adverse effects were reported in breastfed infants whose mothers 
received LEV 1000 to 3500 mg daily. 
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